Michael Parini, Freeline Therapeutics CEO
October 18, 2023 10:45 AM EDTUpdated 11:15 AM
Deals
Cell/Gene Tx

Syn­cona eyes buy­out of gene ther­a­py biotech Free­line af­ter ear­ly da­ta in two Gauch­er pa­tients

Ayisha Sharma

News Reporter

Syn­cona, the ma­jor­i­ty share­hold­er of Free­line Ther­a­peu­tics, has made a bid to ac­quire the biotech less than a month af­ter it re­vealed da­ta from two …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times